About Sage Therapeutics, Inc. - Common Stock (SAGE)
Sage Therapeutics is a biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders. The company aims to address significant unmet medical needs by leveraging its expertise in neuroscience and advanced drug development. Sage Therapeutics is primarily engaged in the research and development of novel therapeutic compounds designed to target neurological and psychiatric conditions, such as major depressive disorder and epilepsy. Through its commitment to scientific rigor and patient-centered innovation, the company seeks to improve the lives of individuals affected by these challenging disorders. Read More
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.
Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Sage Therapeutics, Inc. (NASDAQ: SAGE) to Supernus Pharmaceuticals, Inc. is fair to Sage shareholders. Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable upon achieving certain net sales and commercial milestones.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.
The Ademi Firm is investigating Sage (NASDAQ: SAGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus Pharmaceuticals.
ROCKVILLE, Md. and CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a definitive agreement for Supernus to acquire Sage through a tender offer for $8.50 per share in cash (or an aggregate of approximately $561 million), payable at closing, plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million), for total consideration of $12.00 per share in cash (or an aggregate of up to approximately $795 million). The CVR is payable upon achieving certain net sales and commercial milestones. The transaction is expected to close in the third quarter of 2025.
Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that it will host a live webcast on Tuesday, April 29, 2025, at 4:30 p.m. ET to review first quarter 2025 financial results and discuss recent business updates.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sage Therapeutics, Inc. (“Sage” or “the Company”) (NasdaqGM: SAGE).
U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading. Aiming to boost U.S. manufacturing and reduce reliance on global suppliers, new auto tariffs were introduced on Wednesday, which will go into effect from April 3.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sage Therapeutics, Inc. (“Sage” or “the Company”) (NasdaqGM: SAGE).
